Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies.

Our vision is bold—to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies.

Our vision is practical—to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.

The foundational technology and intellectual property for Syndax are based on the work of Ronald Evans, PhD, recipient of the 2004 Albert Lasker Award for Basic Medical Research and a Member of the National Academy of Sciences. This work focuses on the scientific premise of unlocking the synergistic potential of combination therapies with enhanced anticancer properties. The Syndax approach to scientifically rational combination therapy will improve cancer treatment in a variety of solid tumors and hematological cancers.

Syndax is dedicated to the principles of achievement, integrity, excellence in science, collaboration, compassion, and teamwork. With high ethical standards and mutual respect, Syndax intends to serve the best interests of patients, medical professionals, its employees, and the communities in which people work and live. At the same time, Syndax aims to provide significant returns to its stockholders through its pursuit of scientific and operational excellence.

Syndax is committed to cancer patients and their families by introducing innovations in cancer therapy that address unmet needs, supporting their information needs, and working as advocates on their behalf.

The Company's lead program is targeting the histone deacetylase (HDAC) class of enzymes. HDACs are clinically validated for cancer therapy and are among the most promising targets for novel approaches to the development of innovative combination regimens.

The Company's lead product is SNDX-275 (entinostat; formerly MS-275), an oral HDAC inhibitor that acts synergistically with targeted therapies. SNDX-275 is selective for cancer-relevant HDAC isoforms 1, 2, and 3, and preclinical evidence suggests their inhibition can modify the tumor phenotype to restore sensitivity to targeted therapies.

SNDX-275 was licensed from Bayer Schering Pharma AG and is currently in Phase 2 clinical development for several types of cancer.